Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

BACKGROUND: Durvalumab plus gemcitabine and cisplatin has a significant clinical benefit for advanced biliary tract cancer (BTC). However, the high price of durvalumab warrants an exploration of the economics. OBJECTIVE: To investigate the cost-effectiveness of adding durvalumab to gemcitabine and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qiuling, Xie, Ruixiang, Zhong, Wanfu, Liu, Wenbin, Chen, Ting, Qiu, Xiuliang, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979442/
https://www.ncbi.nlm.nih.gov/pubmed/36859267
http://dx.doi.org/10.1186/s12962-023-00429-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979442/
https://www.ncbi.nlm.nih.gov/pubmed/36859267
http://dx.doi.org/10.1186/s12962-023-00429-9

Ejemplares similares